Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Colombo

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Cold Spring Harbor Molecular Case Studies|December 15, 2019
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a <i>KRAS</i>-mutated low-grade serous ovarian cancer patientIlaria Colombo, Swati Garg, Arnavaz Danesh, et al.
ESMO Open|July 29, 2020
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignanciesIlaria Colombo, Eleonora Zaccarelli, Maria Del Grande, et al.
Sexual Development : Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation|April 13, 2016
5α-Reductase-2 Deficiency: Clinical Findings, Endocrine Pitfalls, and Genetic Features in a Large Italian CohortSilvano Bertelloni, Fulvia Baldinotti, Gianni Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2021
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid TumorsIlaria Colombo, Sofia Genta, Federica Martorana, et al.
Cancer Treatment Reviews|September 14, 2024
The active involvement of patients in oncology researchUrsula Ganz-Blaettler, Sarah Jayne Liptrott, Angela Tolotti, et al.
Cancers|June 26, 2025
A Retrospective Assessment of Computed Tomography-Based Body Composition and Toxicity in Ovarian Cancer Patients Treated with PARP InhibitorsMarta Nerone, Giorgio Raia, Maria Del Grande, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
American Journal of Epidemiology|July 6, 2013
Cancer risk among tetrafluoroethylene synthesis and polymerization workersDario Consonni, Kurt Straif, J Morel Symons, et al.
Case Reports in Oncological Medicine|January 12, 2026
Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long-Term SurvivalKatia Roque, Rossana Ruiz, Renier Cruz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)Ilaria Colombo, Kira-Lee Koster, Lisa Holer, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Cold Spring Harbor Molecular Case Studies|December 15, 2019
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a <i>KRAS</i>-mutated low-grade serous ovarian cancer patientIlaria Colombo, Swati Garg, Arnavaz Danesh, et al.
ESMO Open|July 29, 2020
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignanciesIlaria Colombo, Eleonora Zaccarelli, Maria Del Grande, et al.
Sexual Development : Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation|April 13, 2016
5α-Reductase-2 Deficiency: Clinical Findings, Endocrine Pitfalls, and Genetic Features in a Large Italian CohortSilvano Bertelloni, Fulvia Baldinotti, Gianni Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2021
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid TumorsIlaria Colombo, Sofia Genta, Federica Martorana, et al.
Cancer Treatment Reviews|September 14, 2024
The active involvement of patients in oncology researchUrsula Ganz-Blaettler, Sarah Jayne Liptrott, Angela Tolotti, et al.
Cancers|June 26, 2025
A Retrospective Assessment of Computed Tomography-Based Body Composition and Toxicity in Ovarian Cancer Patients Treated with PARP InhibitorsMarta Nerone, Giorgio Raia, Maria Del Grande, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
American Journal of Epidemiology|July 6, 2013
Cancer risk among tetrafluoroethylene synthesis and polymerization workersDario Consonni, Kurt Straif, J Morel Symons, et al.
Case Reports in Oncological Medicine|January 12, 2026
Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long-Term SurvivalKatia Roque, Rossana Ruiz, Renier Cruz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)Ilaria Colombo, Kira-Lee Koster, Lisa Holer, et al.
Pageof 5